Award

NIH Reporter #5R01AI183405-03

Treatment of isoniazid-resistant tuberculosis: closing evidence gaps on safety, effectiveness, and pharmacokinetics of the standard regimen

Recipient

SOCIOS EN SALUD SUCURSAL PERU

Award Amount

$132,182.00

Ceiling

$132,182.00

Awarded

July 07, 2026

Identifier

5R01AI183405-03

The study will assess the safety and effectiveness of the 6Lfx-REZ regimen for isoniazid-resistant, rifampicin-sensitive tuberculosis in Peru, and examine levofloxacin and rifampicin drug levels to inform treatment dosing.

Description

Research to evaluate the safety, tolerability, effectiveness, and pharmacokinetics of the standard regimen for isoniazid-resistant tuberculosis.

View original record